Cargando…
De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
Renal injury almost always accompanies the multisystem organ failure that precedes cardiac transplantation and renal function is further compromised by the nephrotoxicity of calcineurin inhibitors posttransplant. Renal dysfunction in turn causes significant morbidity and mortality. The development o...
Autores principales: | Schenk, Austin D., Anderson, Douglas J., Cole, Robert T., Badell, Idelberto R., Larsen, Christopher P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964935/ https://www.ncbi.nlm.nih.gov/pubmed/32047843 http://dx.doi.org/10.1097/TXD.0000000000000967 |
Ejemplares similares
-
Belatacept Conversion in Kidney After Liver Transplantation
por: Cristea, Octav, et al.
Publicado: (2021) -
Three-year Outcomes After Conversion From Monthly to Every 2-month Belatacept Maintenance Therapy in Kidney Transplant Recipients: Results From a Randomized Controlled Trial
por: Johnson, Aileen C., et al.
Publicado: (2023) -
Efficacy and Safety of Empagliflozin in the Management of Diabetes Mellitus in Heart Transplant Recipients
por: Cehic, Matthew G., et al.
Publicado: (2019) -
Clinical Outcomes of Perioperative Desensitization in Heart Transplant Recipients
por: Plazak, Michael E., et al.
Publicado: (2021) -
Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)